Cardiology – Page 9

Statin Initiation and Follow-Up Testing Are Declining in Young Adults Despite High Cardiovascular Risk

By MedXY 12/25/2025

A large-scale study of over 700,000 young adults reveals a concerning decline in lipid follow-up and statin initiation between 2008 and 2018, highlighting a critical care gap in preventing premature cardiovascular disease during a key window of vulnerability.

Cardiology news

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

By MedXY 12/25/2025

The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of-life improvements for patients with severe aortic stenosis.

Cardiology news

Pulsed Field Ablation Demonstrates Exceptional Safety in Real-World Practice: Insights from the 40,000-Patient MANIFEST-US Study

By MedXY 12/25/2025

The MANIFEST-US study of over 40,000 patients confirms that pulsed field ablation (PFA) for atrial fibrillation maintains a high safety profile in real-world U.S. clinical practice, with a major complication rate of just 0.63% and a complete absence of esophageal fistulas or pulmonary vein stenosis.

Cardiology Infectious Diseases news

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

By MedXY 12/25/2025

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio suggest biological activity and safety in this neglected population.

Cardiology Neurology news

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

By MedXY 12/25/2025

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk for cognitive impairment and structural brain changes.

Cardiology news Oncology

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

By MedXY 12/25/2025

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratification models in cardio-oncology.

Cardiology news Transplantation

Aggressive LDL-C Lowering Post-Heart Transplant: Why Alirocumab Didn’t Halt Early Vasculopathy in the CAVIAR Trial

By MedXY 12/25/2025

The CAVIAR trial reveals that while alirocumab significantly reduces LDL-C in heart transplant recipients, it does not arrest coronary plaque progression within the first year, suggesting that early cardiac allograft vasculopathy may be driven by non-lipid mechanisms.

Cardiology Clinical Updates Neurology news Respiratory

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

By MedXY 12/25/2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective of cardiovascular disease status.

Cardiology Infectious Diseases news Public Health

High-Dose Influenza Vaccination Reduces Hospitalizations and Cardiovascular Events in Older Adults: Insights from the FLUNITY-HD Pooled Analysis

By MedXY 12/25/2025

The FLUNITY-HD pooled analysis of over 466,000 older adults demonstrates that high-dose inactivated influenza vaccine (HD-IIV) significantly reduces hospitalizations for influenza, pneumonia, and cardiovascular causes, including a 21.3% reduction in heart failure admissions, compared to standard-dose vaccines.

Cardiology news

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

By MedXY 12/25/2025

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Cardiology news

Coramitug Significantly Reduces NT-proBNP in Transthyretin Amyloid Cardiomyopathy: Phase 2 Trial Results

By MedXY 12/25/2025

A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the results suggest a breakthrough in active amyloid clearance.

AI Cardiology news Rheumatology

AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases

By MedXY 12/25/2025

AI-driven analysis of routine chest CTs reveals that coronary artery calcium is highly prevalent and strongly predictive of MACE and mortality in patients with IMIDs, identifying a critical treatment gap in this high-risk population.

Cardiology news Public Health

Beyond the Lead Apron: New Evidence of High Orthopedic and Reproductive Risks in Cardiac Electrophysiology

By MedXY 12/25/2025

A global Heart Rhythm Society survey reveals that 41% of EP professionals suffer from orthopedic injuries and 50% of women face pregnancy complications, highlighting the urgent need for systemic improvements in laboratory ergonomics and radiation safety protocols.

Cardiology news

Beyond the Diastolic Threshold: Isolated Severe Systolic Hypertension as a Potent Predictor of Maternal Risk

By MedXY 12/25/2025

A large-scale analysis of over 115,000 patients demonstrates that isolated severe systolic hypertension (SBP ≥160 mmHg) during delivery admission is independently associated with a dramatic, dose-dependent increase in severe maternal morbidity, including pulmonary edema and renal failure.

Cardiology news OB/GYN & Women's Health

Maternal Pre-existing Atherosclerotic Cardiovascular Disease: A Hidden Risk Factor for Neonatal Health and Long-term Neurodevelopment

By MedXY 12/25/2025

A nationwide cohort study demonstrates that maternal pre-existing ASCVD is independently associated with an increased risk of neonatal complications and long-term neurodevelopmental disorders, persisting regardless of adverse pregnancy outcomes.

Cardiology Internal Medicine news

N-Palmitoyl Glutamine: A Novel Molecular Link Between Exercise, Mitochondrial Efficiency, and Human Longevity

By MedXY 12/25/2025

A groundbreaking study identifies N-palmitoyl glutamine (NPG) as a key molecular transducer of cardiorespiratory fitness. NPG correlates with VO2max, increases with exercise training, predicts lower mortality, and directly enhances mitochondrial function, offering a potential therapeutic target for cardiometabolic health.

Cardiology news Radiology

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

By MedXY 12/25/2025

A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic congestion and right heart failure outcomes.

Cardiology news

Coronary Revascularization in Older Adults: Key Recommendations from the 2025 AHA Scientific Statement

By MedXY 12/25/2025

The 2025 AHA scientific statement provides practical, patient-centered guidance for coronary revascularization in older adults, emphasizing geriatric assessment, individualized strategy selection, and shared decision-making.

Cardiology Internal Medicine news

Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome

By MedXY 12/25/2025

A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with alirocumab effectively mitigates this risk while significantly reducing biomarker levels.

Cardiology news

Thirty Years of ICD Therapy in Brugada Syndrome: Balancing Lifesaving Intervention with Long-term Device Burdens

By MedXY 12/25/2025

This 30-year single-center study evaluates ICD outcomes in Brugada Syndrome, highlighting the efficacy of secondary prevention, the high burden of device-related complications in young patients, and the promising role of epicardial ablation in reducing arrhythmic burden.